false 0001136869 0001136869 2020-03-13 2020-03-13 0001136869 us-gaap:CommonStockMember 2020-03-13 2020-03-13 0001136869 zbh:OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember 2020-03-13 2020-03-13 0001136869 zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember 2020-03-13 2020-03-13 0001136869 zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember 2020-03-13 2020-03-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2020

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-16407

 

13-4151777

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value

 

ZBH

 

New York Stock Exchange

1.414% Notes due 2022

 

ZBH 22A

 

New York Stock Exchange

2.425% Notes due 2026

 

ZBH 26

 

New York Stock Exchange

1.164% Notes due 2027

 

ZBH 27

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(e) of the Exchange Act  

 

 


Item 1.01 Entry into a Material Definitive Agreement.

On March 13, 2020, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc., RBC Capital Markets, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $600.0 million aggregate principal amount of the Company’s 3.050% notes due 2026 (the “2026 Notes”) and $900.0 million aggregate principal amount of the Company’s 3.550% notes due 2030 (the “2030 Notes” and, together with the 2026 Notes, the “Notes”).

The Underwriting Agreement contains representations and warranties and covenants that are customary for transactions of this type. In addition, the Company has agreed to indemnify the Underwriters against certain liabilities on customary terms. The sale of the Notes is scheduled to close on March 20, 2020, subject to the satisfaction of customary closing conditions. Some of the Underwriters and their affiliates have engaged in, and may in the future engage in, commercial banking, financial advisory, investment banking, lending and other commercial dealings in the ordinary course of their business with the Company or its affiliates, including participating as lenders under the Company’s credit facilities, for which they have received, and may in the future receive, customary fees and commissions. In addition, Wells Fargo Securities, LLC, an Underwriter for the offering, is an affiliate of the trustee under the indenture described below. Also, to the extent that the Underwriters or their affiliates own any of the Company’s $1.5 billion outstanding aggregate principal amount of 2.700% Senior Notes due 2020 (the “2020 Notes”), they would receive their proportionate share of the net proceeds that the Company uses from the offering of the Notes to repay the 2020 Notes at maturity.

The Notes will be issued pursuant to a seventh supplemental indenture, to be dated as of March 20, 2020, to the Indenture (the “Base Indenture”) dated as of November 17, 2009 between the Company and Wells Fargo Bank, National Association, as trustee. The 2026 Notes will bear interest at a rate of 3.050% per annum, which interest will be payable semi-annually in arrears on January 15 and July 15 of each year, commencing on July 15, 2020. The 2026 Notes will mature on January 15, 2026. The 2030 Notes will bear interest at a rate of 3.550% per annum, which interest will be payable semi-annually in arrears on March 20 and September 20 of each year, commencing on September 20, 2020. The 2030 Notes will mature on March 20, 2030.

The offering of the Notes was made pursuant to the Registration Statement on Form S-3 (Registration No. 333-229882), the prospectus dated February 26, 2019 and the related prospectus supplement dated March 13, 2020.

A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference. The Base Indenture was incorporated by reference into the Registration Statement.


Item 9.01 Financial Statements and Exhibits.

  (d) Exhibits

Exhibit 

No.

   

Description

         
 

1.1

   

Underwriting Agreement dated as of March 13, 2020 among Zimmer Biomet Holdings, Inc., BofA Securities, Inc., Citigroup Global Markets Inc., RBC Capital Markets, LLC and Wells Fargo Securities, LLC

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding the closing of the offering of the Notes and the Company’s intended use of proceeds. Forward-looking statements may be identified by the use of forward-looking terms such as “intends,” “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could” and similar expressions or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements, including risks that the offering of the Notes is not consummated on the anticipated terms, if at all. For a list and description of some of such risks, uncertainties and changes in circumstances, see the Company’s filings with the Securities and Exchange Commission (the “SEC”). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this Current Report on Form 8-K are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this Current Report on Form 8-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 19, 2020

ZIMMER BIOMET HOLDINGS, INC.

     

By:

 

/s/ Chad F. Phipps

Name:

 

Chad F. Phipps

Title:

 

Senior Vice President, General Counsel

 

and Secretary 

Zimmer Biomet (NYSE:ZBH)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Zimmer Biomet Charts.
Zimmer Biomet (NYSE:ZBH)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Zimmer Biomet Charts.